Terms: = Liver cancer AND FSTL3, FLRG, 10272, ENSG00000070404, O95633
5 results:
1. fstl3 promotes tumor immune evasion and attenuates response to anti-PD1 therapy by stabilizing c-Myc in colorectal cancer.
Li H; Zheng N; Guo A; Tang W; Li M; Cao Y; Ma X; Cao H; Ma Y; Wang H; Zhao S
Cell Death Dis; 2024 Feb; 15(2):107. PubMed ID: 38302412
[TBL] [Abstract] [Full Text] [Related]
2. Stroma-associated fstl3 is a factor of calcium channel-derived tumor fibrosis.
Li JP; Liu YJ; Yin Y; Li RN; Huang W; Zou X
Sci Rep; 2023 Dec; 13(1):21317. PubMed ID: 38044354
[TBL] [Abstract] [Full Text] [Related]
3. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
[TBL] [Abstract] [Full Text] [Related]
4. Activins and activin antagonists in hepatocellular carcinoma.
Deli A; Kreidl E; Santifaller S; Trotter B; Seir K; Berger W; Schulte-Hermann R; Rodgarkia-Dara C; Grusch M
World J Gastroenterol; 2008 Mar; 14(11):1699-709. PubMed ID: 18350601
[TBL] [Abstract] [Full Text] [Related]
5. Human autopsy tissue concentrations of mitoxantrone.
Stewart DJ; Green RM; Mikhael NZ; Montpetit V; Thibault M; Maroun JA
Cancer Treat Rep; 1986 Nov; 70(11):1255-61. PubMed ID: 3768871
[TBL] [Abstract] [Full Text] [Related]
